Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

AIM: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated patients' treatment preferences and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauch, Teri J, Chladek, Michael R, Cataland, Spero, Chaturvedi, Shruti, Dixon, Bradley P, Garlo, Katherine, Gasteyger, Christoph, Java, Anuja, Leguizamo, Jorge, Lloyd-Price, Lucy, Pham, Tan P, Symonds, Tara, Tomazos, Ioannis, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690411/
https://www.ncbi.nlm.nih.gov/pubmed/37515502
http://dx.doi.org/10.57264/cer-2023-0036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690411/
https://www.ncbi.nlm.nih.gov/pubmed/37515502
http://dx.doi.org/10.57264/cer-2023-0036

Ejemplares similares